GGrantIndex
Sort

40,608 grants matching prostate cancer

Pharmcogenomic dissection of mTOR translational targets in prostate cancer

$386,369
Davide Ruggero · University Of California, San Francisco · R01 · FY2011 · CA

Signaling Network Dynamics in Metastatic Prostate Cancer

$386,344
David S. Lawrence · Univ Of North Carolina Chapel Hill · R01 · FY2013 · CA

Understanding Resistance to Next Generation Antiandrogens

$386,325
Charles L Sawyers · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA

Metabolic Imaging of the Prostate Using 3D MRSI

$386,311
University Of California San Francisco · R01 · FY2005 · CA

Vitamin D Analogs for Chemoprevention of Prostate CAncer

$386,285
Barbara A Foster · Roswell Park Cancer Institute Corp · R01 · FY2009 · CA

Ligand-mediated, vehicle-free delivery of small RNAs

$386,276
Andrea L Kasinski · Purdue University · R01 · FY2023 · CA

Pure Flavonolignans from S. marianum in Prostate Cancer

$386,258
Nicholas Hunter Oberlies · Research Triangle Institute · R01 · FY2008 · CA

Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants

$386,250
Robert K Ernst · University Of Maryland Baltimore · R01 · FY2019 · AI

Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants

$386,250
Robert K Ernst · University Of Maryland Baltimore · R01 · FY2018 · AI

Howard University Research Center for Minority Health and Health Disparities

$386,250
William M Southerland · Howard University · U54 · FY2020 · MD

Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants

$386,250
Robert K Ernst · University Of Maryland Baltimore · R01 · FY2017 · AI

Prostatectomy vs watchful waiting - a randomized trial.

$386,237
Gunnar Steineck · Karolinska Institute · R01 · FY2010 · CA

(PQA1) The antipsychotic thioridazine protects against medulloblastoma (MB): volu

$386,223
Lily Y Jan · University Of California, San Francisco · R01 · FY2014 · CA

Targeted tumoricidal bacteria

$386,199
Ming Zhao · Anticancer, Inc. · R44 · FY2011 · CA

Controlled Release of Macromolecules

$386,153
Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2011 · EB

Development of biophysical approaches to investigate high-resolution structure and dynamics of membrane proteins

$386,143
Ayyalusamy Ramamoorthy · University Of Michigan At Ann Arbor · R35 · FY2021 · GM

TRANSGENIC MOUSE MODELS FOR STUDYING PROSTATE/GU DISEASE

$386,125
Washington University · R01 · FY2000 · DK

Functional characterization of prostate cancer risk loci by high throughput sequencing

$386,114
Liang Wang · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2020 · CA

Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care

$386,100
Jason L Vassy · Harvard Medical School · R35 · FY2020 · HG

Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care

$386,100
Jason L Vassy · Harvard Medical School · R35 · FY2021 · HG

Pragmatic randomized trial of polygenic risk scoring for common diseases in primary care

$386,100
Jason L Vassy · Harvard Medical School · R35 · FY2019 · HG

CD8+ T Cell-Mediated Immunotherapy of Autochthonous SV40 T Antigen-Induced Tumors

$386,069
Todd D Schell · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2010 · CA

Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markers

$386,067
Sigrid Carlsson · Sloan-Kettering Inst Can Research · U01 · FY2023 · CA

Immune activation by necroptotic cell death

$386,054
Andrew Atwell Oberst · University Of Washington · R01 · FY2019 · CA

Ligand-mediated, vehicle-free delivery of small RNAs

$386,024
Andrea L Kasinski · Purdue University · R01 · FY2025 · CA